These adaptive, randomized, open-label, controlled clinical trials are being conducted in collaboration with countries around the world through the World Health Organization (WHO). The aim is to provide robust results on which drugs can save lives in those hospitalized with severe or critical COVID-19. The initial phase of the trial evaluated remdesivir, hydroxychloroquine, lopinavir, and interferon.
The CATCO study, led by Dr. Srinivas Murthy, is a CIHR-funded substudy of the Solidarity Trial. The study involved 52 Canadian hospitals and evaluated the effect of remdesivir in more than 1,200 hospitalized patients with COVID-19. Learn more here.
In 2021, the WHO began the next phase in the Solidarity Trial. Solidarity Trial PLUS will enroll hospitalized patients to test three new drugs in hospitalized COVID-19 patients. These therapies - artesunate, imatinib and infliximab – were selected by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients. Learn more here.